Market Research Report
Global Next-Generation Breast Cancer Diagnostic and Screening Market: Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030
|Global Next-Generation Breast Cancer Diagnostic and Screening Market: Focus on Products, Technologies, Cancer Sub-Type, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030|
Published: August 6, 2020
BIS Research Inc.
Content info: 206 Pages
Delivery time: 1-2 business days
"Global Next-Generation Breast Cancer Diagnostics and Screening Market to Reach $10.48 Billion by 2030."
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Invitae Corporation, Thermo Fisher Scientific Inc., Biocept, Inc., Biotheranostics, Agendia N.V., Lucence Diagnostics Pte Ltd, Agilent Technologies, Inc., Myriad Genetics, Inc, Fulgent Genetics, Centogene N.V., and Ambry Genetics
Our healthcare experts have found next generation breast cancer diagnostics and screening market to be one of the most rapidly evolving markets and the global market for next generation breast cancer diagnostics and screening market is predicted to grow at a CAGR of 13.12% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising incidence of breast cancer patients inciting the development of rapid diagnostic assays, significant innovation resulting in market pull, shift from centralized to decentralized laboratories, and significant external funding for executing R&D exercises.
The market is favoured by the development of genomic-based assays for early diagnosis and prognosis of metastatic and recurrent breast cancers. The gradual increase in the prevalence of breast cancer patients, globally has furthered the breast cancer diagnostics market.
Furthermore, several diagnostic companies are focusing on the development of biomarker-diagnostics with higher sensitivity and low turn-around time to benefit the patients, providing diagnosis at an early stage.
Within the research report, the market is segmented on the basis of product type, application, technology, disease end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
The exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of rapid diagnostics providing information on genetic mutation and patients good candidate for adjuvant chemotherapy or hormonal therapy. Due to the diverse product portfolio and intense market penetration, Abbott Laboratories has been a pioneer in this field and been a significant competitor in this market.
Several other companies such as F. Hoffman-La Roche Ltd, Myriad Genetics Inc., and Agendia, among others, have launched diagnostics assays for breast cancer, such as Foundation One CDx, EndoPredict, and Mammaprint, among others.
On the basis of region, North America holds the largest share of next generation breast cancer diagnostics and screening market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.